๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Comparative bioavailability of josamycin, a macrolide antibiotic, from a tablet and solution and the influence of dissolution on in vivo release

โœ Scribed by M. Skinner; I. Kanfer


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
192 KB
Volume
19
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


The bioavailability of josamycin from a tablet formulation (2 ร— Josacine ยฎ 500 mg tablets) was investigated and compared with the bioavailability of a solution (containing 1 g drug and buffered at pH 4.0) following administration to six healthy human volunteers. Bioavailability profiles for the solution indicated that the drug was inherently rapidly absorbed with a mean C max of 1.64 90.67 mg L -1 attained at a mean t max of 0.39 90.08 h. The AUC 0 -last was 1.5109 0.687 mg h L -1 . Bioavailability was significantly lower from the tablets than from the solution. Highly variable serum concentration-time profiles were obtained from the tablets and C max values ranged from 0.05 to 0.71 mg L -1 with a t max range of 0.33 -2.0 h. AUC 0 -last values ranged from 0.03 to 0.95 mg h L -1 . Dissolution of josamycin from the tablets was generally unaffected at low pH (pH 1.2-5.0), but, rather, limited predominantly by tablet disintegration. However, dissolution was increasingly limited as the pH increased from 5.0 to 9.0. Besides poor disintegration, the particularly low intrinsic dissolution rate and solubility of josamycin at these pH values is likely to further reduce the dissolution rate. Comparison of the solution and tablet serum concentration-time profiles suggests that the absorption of josamycin from the tablets was dissolution rate limited. This is supported by the in vitro dissolution -pH topogram, which suggests that dissolution will be particularly rate limiting if dissolution of whole or parts of tablets occurs in gastro-intestinal fluid above pH 5.0.


๐Ÿ“œ SIMILAR VOLUMES


Comparative in vitro and in vivo bioavai
โœ B. G. Charles; G. A. G. Mogg ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 415 KB ๐Ÿ‘ 2 views

## Abstract A 500 mg dose of naproxen in a caplet formulation (product A) or a tablet (Naprosyn 500, product B) was administered to 14 fasting healthy subjects on two separate occasions, separated by a 1โ€“2 week washout period in an open, randomized crossover. Blood samples were drawn periodically a

In vitro and in vivo assessment of the b
โœ Susan J. Whiting; Dennis K. J. Gorecki; Dennis Jones ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 338 KB ๐Ÿ‘ 1 views

The bioavailability of potassium from orally administered potassium tartrate was evaluated in 20 normal subjects under metabolic balance conditions. Subjects were given 34 mmol potassium (5 tablets of Cal-K@) as a divided dose on each of 2 consecutive days. Urinary excretion of potassium, as determi

Allopurinol: A comparative study of the
โœ Poul Nissen; Linda Pedersen ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 268 KB ๐Ÿ‘ 2 views

A comparative bioavailability study was carried out with two allopurinol products, i.e. Allopurinol tablets 100 mg, DAK, and ApurinB tablets 100 mg, Gea. Eleven healthy volunteers participated and were given a single dose of 200 mg of each product according to the cross-over principle. The bioavaila